-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 16, Nuocheng Jianhua announced that the company's self-developed new tyrosine kinase 2 (Tyrosine Kinase 2, TYK2) inhibitor ICP-332 has completed the first subject administration in China
ICP-332 is a class 1 innovative drug with global independent intellectual property rights of Nuocheng Jianhua, and it is a new type of oral TYK2 inhibitor
As a highly selective new TYK2 inhibitor, ICP-332 has a strong inhibitory activity on TYK2, with a selectivity of about 400 times for JAK2, which can reduce the adverse effects of anemia due to JAK2 inhibition
Note: The original text has been deleted